![](https://ml.globenewswire.com/media/NjE0NTM2NmUtZjZhZC00OWM3LThkNmUtZmE4YWVmOGM5NzA1LTEzMDM0NTE=/tiny/Artiva-Biotherapeutics-Inc-.png)
Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering
SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and …